Amgen's MariTide Phase 2 showed no weight loss plateau at 52 weeks (Nov 2024): The absence of a weight loss plateau effect which both semaglutide and tirzepatide display would be a clinically meaningful differentiation if confirmed in Phase 3, potentially enabling greater sustained weight loss
In some cases, temporary dose reduction or slower titration may allow your body to adapt while minimizing gastrointestinal side effects
A microdosing approach may maintain therapeutic benefit while reducing side effect severity
However, medications like semaglutide at PlexusDx (at $189/mo month-to-month, or from $149/mo on the 6-month plan) remain significantly more affordable than weight-loss surgery, making long-term therapy economically feasible for many patients
Mean change in body weight from baseline: Cl=confidence interval
Results: Mean (range) baseline characteristics of the 957 treated subjects (35% male) were: age 47 (18-86) years, weight 111 (70-244) kg, body mass index 39 (30-80) kg/m2, NFS -0.49 (-4.70 to 4.66), and FIB-4 0.72 (0.14-3.31)
